Personalizing health care

Feasibility and future implications

Brian Godman, Alexander E. Finlayson, Parneet K. Cheema, Eva Zebedin-Brandl, Inaki Gutiérrez-Ibarluzea, Jan Jones, Rickard E. Malmström, Elina Asola, Christoph Baumgärtel, Marion Bennie, Iain Bishop, Anna Bucsics, Stephen Campbell, Eduardo Diogene, Alessandra Ferrario, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Katharine Harris, Alan Haycox & 25 others Harald Herholz, Krystyna Hviding, Saira Jan, Marija Kalaba, Christina Kvalheim, Ott Laius, Sven Ake Lööv, Kamila Malinowska, Andrew Martin, Laura McCullagh, Fredrik Nilsson, Ken Paterson, Ulrich Schwabe, Gisbert Selke, Catherine Sermet, Steven Simoens, Dominik Tomek, Vera Vlahovic-Palcevski, Luka Voncina, Magdalena Wladysiuk, Menno van Woerkom, Durhane Wong-Rieger, Corrine Zara, Raghib Ali, Lars L. Gustafsson

    Research output: Contribution to journalArticle

    Abstract

    Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

    Original languageEnglish (US)
    Article number179
    JournalBMC Medicine
    Volume11
    Issue number1
    DOIs
    StatePublished - Aug 13 2013

    Fingerprint

    Precision Medicine
    Delivery of Health Care
    Costs and Cost Analysis
    Pharmacogenetics
    Patient Care
    Biomarkers
    Phenotype
    Drug Therapy
    Therapeutics
    Pharmaceutical Preparations

    Keywords

    • Biomarkers
    • Drug development
    • Genomics
    • Genotyping
    • Health authorities
    • Healthcare policy
    • Personalized medicine
    • Pharmacogenetics precision medicine
    • Rational use of medicines
    • Reimbursement
    • Targeted treatments

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Godman, B., Finlayson, A. E., Cheema, P. K., Zebedin-Brandl, E., Gutiérrez-Ibarluzea, I., Jones, J., ... Gustafsson, L. L. (2013). Personalizing health care: Feasibility and future implications. BMC Medicine, 11(1), [179]. https://doi.org/10.1186/1741-7015-11-179

    Personalizing health care : Feasibility and future implications. / Godman, Brian; Finlayson, Alexander E.; Cheema, Parneet K.; Zebedin-Brandl, Eva; Gutiérrez-Ibarluzea, Inaki; Jones, Jan; Malmström, Rickard E.; Asola, Elina; Baumgärtel, Christoph; Bennie, Marion; Bishop, Iain; Bucsics, Anna; Campbell, Stephen; Diogene, Eduardo; Ferrario, Alessandra; Fürst, Jurij; Garuoliene, Kristina; Gomes, Miguel; Harris, Katharine; Haycox, Alan; Herholz, Harald; Hviding, Krystyna; Jan, Saira; Kalaba, Marija; Kvalheim, Christina; Laius, Ott; Lööv, Sven Ake; Malinowska, Kamila; Martin, Andrew; McCullagh, Laura; Nilsson, Fredrik; Paterson, Ken; Schwabe, Ulrich; Selke, Gisbert; Sermet, Catherine; Simoens, Steven; Tomek, Dominik; Vlahovic-Palcevski, Vera; Voncina, Luka; Wladysiuk, Magdalena; van Woerkom, Menno; Wong-Rieger, Durhane; Zara, Corrine; Ali, Raghib; Gustafsson, Lars L.

    In: BMC Medicine, Vol. 11, No. 1, 179, 13.08.2013.

    Research output: Contribution to journalArticle

    Godman, B, Finlayson, AE, Cheema, PK, Zebedin-Brandl, E, Gutiérrez-Ibarluzea, I, Jones, J, Malmström, RE, Asola, E, Baumgärtel, C, Bennie, M, Bishop, I, Bucsics, A, Campbell, S, Diogene, E, Ferrario, A, Fürst, J, Garuoliene, K, Gomes, M, Harris, K, Haycox, A, Herholz, H, Hviding, K, Jan, S, Kalaba, M, Kvalheim, C, Laius, O, Lööv, SA, Malinowska, K, Martin, A, McCullagh, L, Nilsson, F, Paterson, K, Schwabe, U, Selke, G, Sermet, C, Simoens, S, Tomek, D, Vlahovic-Palcevski, V, Voncina, L, Wladysiuk, M, van Woerkom, M, Wong-Rieger, D, Zara, C, Ali, R & Gustafsson, LL 2013, 'Personalizing health care: Feasibility and future implications', BMC Medicine, vol. 11, no. 1, 179. https://doi.org/10.1186/1741-7015-11-179
    Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J et al. Personalizing health care: Feasibility and future implications. BMC Medicine. 2013 Aug 13;11(1). 179. https://doi.org/10.1186/1741-7015-11-179
    Godman, Brian ; Finlayson, Alexander E. ; Cheema, Parneet K. ; Zebedin-Brandl, Eva ; Gutiérrez-Ibarluzea, Inaki ; Jones, Jan ; Malmström, Rickard E. ; Asola, Elina ; Baumgärtel, Christoph ; Bennie, Marion ; Bishop, Iain ; Bucsics, Anna ; Campbell, Stephen ; Diogene, Eduardo ; Ferrario, Alessandra ; Fürst, Jurij ; Garuoliene, Kristina ; Gomes, Miguel ; Harris, Katharine ; Haycox, Alan ; Herholz, Harald ; Hviding, Krystyna ; Jan, Saira ; Kalaba, Marija ; Kvalheim, Christina ; Laius, Ott ; Lööv, Sven Ake ; Malinowska, Kamila ; Martin, Andrew ; McCullagh, Laura ; Nilsson, Fredrik ; Paterson, Ken ; Schwabe, Ulrich ; Selke, Gisbert ; Sermet, Catherine ; Simoens, Steven ; Tomek, Dominik ; Vlahovic-Palcevski, Vera ; Voncina, Luka ; Wladysiuk, Magdalena ; van Woerkom, Menno ; Wong-Rieger, Durhane ; Zara, Corrine ; Ali, Raghib ; Gustafsson, Lars L. / Personalizing health care : Feasibility and future implications. In: BMC Medicine. 2013 ; Vol. 11, No. 1.
    @article{efb09cef70c346d0a92cf60bbe85d897,
    title = "Personalizing health care: Feasibility and future implications",
    abstract = "Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.",
    keywords = "Biomarkers, Drug development, Genomics, Genotyping, Health authorities, Healthcare policy, Personalized medicine, Pharmacogenetics precision medicine, Rational use of medicines, Reimbursement, Targeted treatments",
    author = "Brian Godman and Finlayson, {Alexander E.} and Cheema, {Parneet K.} and Eva Zebedin-Brandl and Inaki Guti{\'e}rrez-Ibarluzea and Jan Jones and Malmstr{\"o}m, {Rickard E.} and Elina Asola and Christoph Baumg{\"a}rtel and Marion Bennie and Iain Bishop and Anna Bucsics and Stephen Campbell and Eduardo Diogene and Alessandra Ferrario and Jurij F{\"u}rst and Kristina Garuoliene and Miguel Gomes and Katharine Harris and Alan Haycox and Harald Herholz and Krystyna Hviding and Saira Jan and Marija Kalaba and Christina Kvalheim and Ott Laius and L{\"o}{\"o}v, {Sven Ake} and Kamila Malinowska and Andrew Martin and Laura McCullagh and Fredrik Nilsson and Ken Paterson and Ulrich Schwabe and Gisbert Selke and Catherine Sermet and Steven Simoens and Dominik Tomek and Vera Vlahovic-Palcevski and Luka Voncina and Magdalena Wladysiuk and {van Woerkom}, Menno and Durhane Wong-Rieger and Corrine Zara and Raghib Ali and Gustafsson, {Lars L.}",
    year = "2013",
    month = "8",
    day = "13",
    doi = "10.1186/1741-7015-11-179",
    language = "English (US)",
    volume = "11",
    journal = "BMC Medicine",
    issn = "1741-7015",
    publisher = "BioMed Central",
    number = "1",

    }

    TY - JOUR

    T1 - Personalizing health care

    T2 - Feasibility and future implications

    AU - Godman, Brian

    AU - Finlayson, Alexander E.

    AU - Cheema, Parneet K.

    AU - Zebedin-Brandl, Eva

    AU - Gutiérrez-Ibarluzea, Inaki

    AU - Jones, Jan

    AU - Malmström, Rickard E.

    AU - Asola, Elina

    AU - Baumgärtel, Christoph

    AU - Bennie, Marion

    AU - Bishop, Iain

    AU - Bucsics, Anna

    AU - Campbell, Stephen

    AU - Diogene, Eduardo

    AU - Ferrario, Alessandra

    AU - Fürst, Jurij

    AU - Garuoliene, Kristina

    AU - Gomes, Miguel

    AU - Harris, Katharine

    AU - Haycox, Alan

    AU - Herholz, Harald

    AU - Hviding, Krystyna

    AU - Jan, Saira

    AU - Kalaba, Marija

    AU - Kvalheim, Christina

    AU - Laius, Ott

    AU - Lööv, Sven Ake

    AU - Malinowska, Kamila

    AU - Martin, Andrew

    AU - McCullagh, Laura

    AU - Nilsson, Fredrik

    AU - Paterson, Ken

    AU - Schwabe, Ulrich

    AU - Selke, Gisbert

    AU - Sermet, Catherine

    AU - Simoens, Steven

    AU - Tomek, Dominik

    AU - Vlahovic-Palcevski, Vera

    AU - Voncina, Luka

    AU - Wladysiuk, Magdalena

    AU - van Woerkom, Menno

    AU - Wong-Rieger, Durhane

    AU - Zara, Corrine

    AU - Ali, Raghib

    AU - Gustafsson, Lars L.

    PY - 2013/8/13

    Y1 - 2013/8/13

    N2 - Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

    AB - Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

    KW - Biomarkers

    KW - Drug development

    KW - Genomics

    KW - Genotyping

    KW - Health authorities

    KW - Healthcare policy

    KW - Personalized medicine

    KW - Pharmacogenetics precision medicine

    KW - Rational use of medicines

    KW - Reimbursement

    KW - Targeted treatments

    UR - http://www.scopus.com/inward/record.url?scp=84887911877&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84887911877&partnerID=8YFLogxK

    U2 - 10.1186/1741-7015-11-179

    DO - 10.1186/1741-7015-11-179

    M3 - Article

    VL - 11

    JO - BMC Medicine

    JF - BMC Medicine

    SN - 1741-7015

    IS - 1

    M1 - 179

    ER -